Hématologie clinique et thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, France.
Centre de Référence des Microangiopathies thrombotiques, AP-HP.6, Paris, France.
Eur J Haematol. 2021 Apr;106(4):467-472. doi: 10.1111/ejh.13568. Epub 2020 Dec 22.
Relapsed/refractory peripheral T-cell lymphomas (PTCL) have a poor prognosis. We aimed at assessing efficacy of ifosfamide, carboplatin, etoposide (ICE) regimen, a known therapeutic option, to which we added brentuximab-vedotin (BV).
In this study, we retrospectively analyzed patients with PTCL treated with BV-ICE in our center between July 2014 and March 2018.
Fourteen patients received BV-ICE. Median age was 62 years (range, 31-73). Main histological subtypes were PTCL-not otherwise specified (29%), angioimmunoblastic T-cell lymphoma (21%), follicular-T helper (21%), or anaplastic large-cell (15%) lymphomas, all were CD30 positive. Overall response was seen in four (29%) patients, and complete response (CR) in two (14%). Most frequent adverse events were infections, and cytopenia. 2-year progression-free and overall survival were 14% and 17.5%, respectively.
Patients with relapsed/refractory PTCL treated with BV-ICE can achieve CR, but few had a sustained response. This association should preferably be used as a bridge to stem cell transplant or be followed by maintenance therapy.
复发性/难治性外周 T 细胞淋巴瘤（PTCL）预后较差。我们旨在评估异环磷酰胺、卡铂、依托泊苷（ICE）方案的疗效，该方案是一种已知的治疗选择，我们在此基础上添加了 Brentuximab-vedotin（BV）。
在这项研究中，我们回顾性分析了 2014 年 7 月至 2018 年 3 月期间在我们中心接受 BV-ICE 治疗的 PTCL 患者。
14 名患者接受了 BV-ICE 治疗。中位年龄为 62 岁（范围 31-73 岁）。主要组织学亚型为未特指的外周 T 细胞淋巴瘤（29%）、血管免疫母细胞性 T 细胞淋巴瘤（21%）、滤泡性辅助 T 细胞淋巴瘤（21%）或间变大细胞淋巴瘤（15%），均为 CD30 阳性。4 名（29%）患者出现总体缓解，2 名（14%）患者出现完全缓解（CR）。最常见的不良事件是感染和细胞减少症。2 年无进展生存率和总生存率分别为 14%和 17.5%。
接受 BV-ICE 治疗的复发性/难治性 PTCL 患者可达到 CR，但很少有持续缓解的患者。该联合治疗最好作为干细胞移植的桥梁，或随后进行维持治疗。
